Aliases & Classifications for Agoraphobia

MalaCards integrated aliases for Agoraphobia:

Name: Agoraphobia 12 72 51 41 14 69
Fear of Open Spaces 12

Classifications:



External Ids:

Disease Ontology 12 DOID:593
ICD10 32 F40.0 F40.00
MeSH 41 D000379
NCIt 46 C34362
UMLS 69 C0001818

Summaries for Agoraphobia

Disease Ontology : 12 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary : Agoraphobia, also known as fear of open spaces, is related to social phobia and personality disorder. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Clonazepam and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, thyroid and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 72 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Related Disease Score Top Affiliating Genes
1 social phobia 31.0 MAOA SLC6A4
2 personality disorder 30.6 HTR1A MAOA SLC6A4
3 obsessive-compulsive disorder 30.5 HTR1A MAOA SLC6A4
4 panic disorder 29.6 CCKBR HTR1A MAOA PTK7 RGS2 SLC6A2
5 anxiety 29.5 CCKBR HTR1A MAOA PTK7 SLC6A2 SLC6A4
6 generalized anxiety disorder 29.4 HTR1A MAOA RGS2 SLC6A2 SLC6A4
7 major depressive disorder 29.2 HTR1A MAOA SLC6A2 SLC6A4
8 bipolar disorder 29.2 HTR1A MAOA SLC6A2 SLC6A4
9 alcohol dependence 28.9 HTR1A MAOA OPRK1 SLC6A4
10 panic disorder 1 11.2
11 psychosexual disorder 10.4 HTR1A SLC6A4
12 periodic limb movement disorder 10.4 HTR1A SLC6A4
13 premature ejaculation 10.4 HTR1A SLC6A4
14 alexithymia 10.4 HTR1A SLC6A4
15 atypical depressive disorder 10.4 MAOA SLC6A4
16 intermittent explosive disorder 10.4 HTR1A SLC6A4
17 pathological gambling 10.3 MAOA SLC6A4
18 migraine without aura 10.3 HTR1A SLC6A4
19 antisocial personality disorder 10.3 MAOA SLC6A4
20 paranoid schizophrenia 10.3 MAOA SLC6A4
21 early-onset schizophrenia 10.3 MAOA SLC6A4
22 bipolar i disorder 10.3 HTR1A SLC6A4
23 dyspepsia 10.2 HTR1A SLC6A4
24 kleptomania 10.2 HTR1A MAOA SLC6A4
25 obsessive-compulsive personality disorder 10.2 PIR SLC6A4
26 brunner syndrome 10.2 HTR1A MAOA SLC6A4
27 postpartum depression 10.2 HTR1A MAOA SLC6A4
28 schizoid personality disorder 10.2 HTR1A PIR
29 borderline personality disorder 10.2 HTR1A MAOA SLC6A4
30 serotonin syndrome 10.2 HTR1A MAOA SLC6A4
31 endogenous depression 10.2 HTR1A MAOA SLC6A4
32 chronic fatigue syndrome 10.2 HTR1A MAOA SLC6A4
33 migraine with or without aura 1 10.1 HTR1A MAOA SLC6A4
34 cocaine abuse 10.1 SLC6A2 SLC6A4
35 sudden infant death syndrome 10.1 HTR1A MAOA SLC6A4
36 bulimia nervosa 1 10.1 MAOA SLC6A4
37 oppositional defiant disorder 10.0 MAOA SLC6A2 SLC6A4
38 conduct disorder 10.0 MAOA SLC6A4
39 blood group, i system 10.0
40 eating disorder 10.0
41 dysthymic disorder 10.0 MAOA PIR SLC6A4
42 opiate dependence 9.9 OPRK1 SLC6A4
43 aging 9.9
44 separation anxiety disorder 9.9
45 thyroiditis 9.9
46 autism 9.9 GRPR HTR1A MAOA SLC6A4
47 substance abuse 9.9 MAOA SLC6A4
48 opioid addiction 9.8 CCKBR OPRK1
49 hypochondriasis 9.8
50 melancholia 9.8

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to Agoraphobia

Symptoms & Phenotypes for Agoraphobia

MGI Mouse Phenotypes related to Agoraphobia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 SLC6A4 CCKBR GRPR HTR1A MAOA OPRK1
2 cardiovascular system MP:0005385 9.76 SLC6A4 CCKBR STMN1 HTR1A MAOA PTK7
3 homeostasis/metabolism MP:0005376 9.56 SLC6A4 CCKBR STMN1 GRPR HTR1A MAOA
4 nervous system MP:0003631 9.28 SLC6A4 CCKBR STMN1 HTR1A MAOA OPRK1

Drugs & Therapeutics for Agoraphobia

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
2
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
3
Sertraline Approved Phase 4 79617-96-2 68617
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 1 28981-97-7 2118
6 Anticonvulsants Phase 4
7 Antidepressive Agents Phase 4,Phase 3
8 Antidepressive Agents, Second-Generation Phase 4,Phase 3
9 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3
11 GABA Agents Phase 4,Phase 1
12 GABA Modulators Phase 4,Phase 1
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 1
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
15 Psychotropic Drugs Phase 4,Phase 3,Phase 1
16
Serotonin Phase 4,Phase 3 50-67-9 5202
17 Serotonin Agents Phase 4,Phase 3
18 Serotonin Uptake Inhibitors Phase 4,Phase 3
19 Central Nervous System Stimulants Phase 4
20 Dopamine Agents Phase 4
21 Dopamine Uptake Inhibitors Phase 4
22 Lisdexamfetamine Dimesylate Phase 4
23 Anti-Anxiety Agents Phase 4,Phase 1
24 Central Nervous System Depressants Phase 4,Phase 1
25 Hypnotics and Sedatives Phase 4,Phase 1
26 Tranquilizing Agents Phase 4,Phase 1
27
Cycloserine Approved Phase 2 68-41-7 6234 401
28 Anti-Bacterial Agents Phase 2
29 Antibiotics, Antitubercular Phase 2
30 Anti-Infective Agents Phase 2
31 Antimetabolites Phase 2
32 Antitubercular Agents Phase 2
33 Renal Agents Phase 2
34
Citalopram Approved 59729-33-8 2771
35
Adenosine Approved, Investigational 58-61-7 60961
36
Magnesium Sulfate Approved, Investigational, Vet_approved 7487-88-9 24083
37
Caffeine Approved, Nutraceutical 58-08-2 2519
38 Antiparkinson Agents
39 Autonomic Agents
40 Cholinergic Agents
41 Cholinergic Antagonists
42 Muscarinic Antagonists
43 Parasympatholytics
44 Peripheral Nervous System Agents
45 Analgesics
46 Anti-Arrhythmia Agents
47 Phosphodiesterase Inhibitors
48 Purinergic P1 Receptor Antagonists
49 Vasodilator Agents

Interventional clinical trials:

(show top 50) (show all 58)

# Name Status NCT ID Phase Drugs
1 Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
2 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
3 Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
4 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
5 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
6 A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
7 Mechanisms of Panic Disorders Treatment Unknown status NCT01323556 Phase 2, Phase 3
8 Virtual Reality Exposure Therapy in Agoraphobic Participants Completed NCT00734370 Phase 2, Phase 3
9 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
10 Comparison of Psychotherapy Programs to Treat Panic Disorder Completed NCT00353470 Phase 3
11 Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder Completed NCT00845260 Phase 3
12 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
13 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
14 Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia Completed NCT01928823 Phase 2 D-Cycloserine
15 Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia Completed NCT00576719 Phase 2
16 Exposure Therapy for Fear of Falling in Older Adults Completed NCT01609322 Phase 2
17 Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled Trial Completed NCT01076777 Phase 2
18 Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic Disorder Completed NCT00705380 Phase 2
19 Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia Recruiting NCT01680237 Phase 2
20 Improve: Integrating Emotion Focused Components Into Psychological Therapy Recruiting NCT02822443 Phase 2
21 The Modular Protocol for Mental Health (MPMH) Enrolling by invitation NCT03143634 Phase 1, Phase 2
22 An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites Completed NCT01330472 Phase 1 Xanax XR tablets 3 mg (sourced from Caugus);Xanax XR tablets 3 mg (sourced from Barceloneta)
23 Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia Unknown status NCT00129610
24 Virtual Reality and Concept of Control in the Treatment of Acrophobia Unknown status NCT02020824
25 Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway Unknown status NCT02150265
26 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia Completed NCT01928810
27 Thought Field Therapy and Cognitive Therapy for Agoraphobia Completed NCT00932919
28 Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia Completed NCT01446172
29 Cognitive Behavioral Therapy in Panic Disorder Completed NCT00772746
30 Internet-based Exposure Therapy for Panic Disorder Completed NCT03061448
31 Physical Activity and Cognitive Behavioural Therapy in Panic Disorder Completed NCT01788800
32 Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia Completed NCT00004367
33 Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder? Completed NCT00202709
34 Cognitive Behavior Psychotherapy in Panic Disorder Completed NCT01025908
35 Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction Completed NCT00004366
36 Interpretation Modification Program for Social Phobia Completed NCT00684541
37 Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months Completed NCT00711737
38 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
39 Genetic Causes of Panic Disorder Completed NCT00083265
40 Youth Mayo Clinic Anxiety Coach Pilot Study Completed NCT02205177
41 Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly Completed NCT02387047
42 Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders Recruiting NCT02811458
43 Providing Tools for Effective Care and Treatment of Anxiety Disorders Recruiting NCT02605668
44 Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders Recruiting NCT02345668 Treatment as Usual (Pharmacological Treatment)
45 Efficacy of a Transdiagnostic Internet-based Protocol in Community Sample Recruiting NCT02578758
46 Examining the Effects of Reduced Environmental Stimulation on Anxiety Recruiting NCT03051074
47 Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment Recruiting NCT02305537
48 Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli Recruiting NCT03206437
49 Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety Recruiting NCT02810171
50 Expectation of Unpleasant Events in Anxiety Disorders Recruiting NCT00055224

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

Anatomical Context for Agoraphobia

MalaCards organs/tissues related to Agoraphobia:

38
Brain, Thyroid, Cortex, Pituitary, Amygdala, Breast, Testes

Publications for Agoraphobia

Articles related to Agoraphobia:

(show top 50) (show all 556)
# Title Authors Year
1
Stress hormone response to the DEX-CRH test and its relation to psychotherapy outcome in panic disorder patients with and without agoraphobia. ( 29391399 )
2018
2
PanelA Report, IPA Congress Buenos Aires 2017: Claustro-agoraphobia, Bertram Lewin, and the oral triad 6 April 2017. ( 29148571 )
2017
3
Fear of Fear and Broad Dimensions of Psychopathology over the Course of Cognitive Behavioural Therapy for Panic Disorder with Agoraphobia in Japan. ( 29259145 )
2017
4
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. ( 27861457 )
2017
5
Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. ( 28845177 )
2017
6
Two Novel Cognitive Behavioral Therapy-Based Mobile Apps for Agoraphobia: Randomized Controlled Trial. ( 29175809 )
2017
7
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. ( 28345374 )
2017
8
Neurobiological and clinical effects of fNIRS-controlled rTMS in patients with panic disorder/agoraphobia during cognitive-behavioural therapy. ( 29085773 )
2017
9
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. ( 28418834 )
2017
10
No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial. ( 28820746 )
2017
11
Thought Field Therapy Compared to Cognitive Behavioral Therapy and Wait-List for Agoraphobia: A Randomized, Controlled Study with a 12-Month Follow-up. ( 28676782 )
2017
12
Support Vector Machine Analysis of Functional Magnetic Resonance Imaging of Interoception Does Not Reliably Predict Individual Outcomes of Cognitive Behavioral Therapy in Panic Disorder with Agoraphobia. ( 28649205 )
2017
13
Transdiagnostic group CBT vs. standard group CBT for depression, social anxiety disorder and agoraphobia/panic disorder: Study protocol for a pragmatic, multicenter non-inferiority randomized controlled trial. ( 28114915 )
2017
14
Comorbidity and Suicidality in Patients Diagnosed with Panic Disorder/Agoraphobia and Major Depression. ( 28636577 )
2017
15
Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. ( 27725796 )
2016
16
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). ( 27450798 )
2016
17
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. ( 27061246 )
2016
18
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. ( 26588081 )
2016
19
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. ( 27385412 )
2016
20
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. ( 27071857 )
2016
21
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. ( 27594602 )
2016
22
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. ( 26877119 )
2016
23
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. ( 27423353 )
2016
24
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. ( 27828703 )
2016
25
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. ( 27235836 )
2016
26
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. ( 27449053 )
2016
27
Agoraphobia Related to Unassertiveness in Panic Disorder. ( 26915016 )
2016
28
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( 26663632 )
2016
29
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. ( 27019339 )
2016
30
Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. ( 27123977 )
2016
31
Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. ( 26837851 )
2016
32
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. ( 27730622 )
2016
33
Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. ( 26361067 )
2015
34
Ghrelin and lipid levels in panic disorder before and after treatment and their relationship with agoraphobia. ( 26400133 )
2015
35
Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. ( 25722042 )
2015
36
A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. ( 26443228 )
2015
37
Agoraphobia and Melancholia: Thoughts on Milrod's "Emptiness in Agoraphobia Patients". ( 26263925 )
2015
38
Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. ( 25875094 )
2015
39
Frontal cortex absolute beta power measurement in Panic Disorder with Agoraphobia patients. ( 26093831 )
2015
40
Social Anxiety Disorder and Agoraphobia in Dermatology Patients; Two Cases and a Review of the Literature. ( 25721467 )
2015
41
Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. ( 26308791 )
2015
42
Intensive behavioral therapy for agoraphobia. ( 25479049 )
2015
43
CLINICAL CONSEQUENCES OF THE REVISED DSM-5 DEFINITION OF AGORAPHOBIA IN TREATMENT-SEEKING ANXIOUS YOUTH. ( 25845579 )
2015
44
Metabolic decoupling in daily life in patients with panic disorder and agoraphobia. ( 26028550 )
2015
45
Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. ( 26480214 )
2015
46
The combined use of virtual reality exposure in the treatment of agoraphobia. ( 26150057 )
2015
47
Predictors of short- and long-term avoidance in completers of inpatient group interventions for agoraphobia. ( 25917291 )
2015
48
An admixture analysis of age of onset in agoraphobia. ( 25898330 )
2015
49
The role of safety behaviors in exposure-based treatment for panic disorder and agoraphobia: associations to symptom severity, treatment course, and outcome. ( 25445073 )
2014
50
The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. ( 25218272 )
2014

Variations for Agoraphobia

Expression for Agoraphobia

Search GEO for disease gene expression data for Agoraphobia.

Pathways for Agoraphobia

GO Terms for Agoraphobia

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.86 CCKBR GRPR HTR1A OPRK1 PTK7 RGS2
2 membrane GO:0016020 9.85 CCKBR GRPR HTR1A MAOA OPRK1 PTK7
3 integral component of plasma membrane GO:0005887 9.5 CCKBR GRPR HTR1A OPRK1 PTK7 SLC6A2
4 neuron projection GO:0043005 9.02 OPRK1 RGS2 SLC6A2 SLC6A4 STMN1

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.88 CCKBR GRPR HTR1A OPRK1 PTK7 STMN1
2 social behavior GO:0035176 9.46 GRPR SLC6A4
3 neurotransmitter transport GO:0006836 9.43 SLC6A2 SLC6A4
4 vasoconstriction GO:0042310 9.37 HTR1A SLC6A4
5 sensory perception GO:0007600 9.32 CCKBR OPRK1
6 behavior GO:0007610 9.26 HTR1A OPRK1
7 monoamine transport GO:0015844 9.16 SLC6A2 SLC6A4
8 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.13 CCKBR GRPR OPRK1
9 dopamine uptake involved in synaptic transmission GO:0051583 8.62 SLC6A2 SLC6A4

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-tubulin binding GO:0048487 9.16 RGS2 SLC6A2
2 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A4
3 dopamine:sodium symporter activity GO:0005330 8.62 SLC6A2 SLC6A4

Sources for Agoraphobia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....